<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044852</identifier>
<setSpec>0378-4835</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Phase II assay with pegilated liposomal doxorubicin and cyclophosphamide in patients with advanced ovary cancer resistant to platinum-based drugs</dc:title>
<dc:description xml:lang="en">Purpose: To evaluate the efficacy and safeness of patients with advanced ovary cancer resistant toplatinum-based drugs receiving a regime of liposomal adriamycin 35 mg/m2 and cyclophosphamide600 mg/m2 day 1 every 28 days, up to a maximum of 8 cycles.Material y methods: Twenty two evaluable patients were enrolled using the indicated phase IImethodology.Results: A response was achieved in 5 out of 21 evaluable patients (23.8%; IC: 5.6-42), with 4 PR(19%; IC: 2.3-35.8) and 1 CR (4.8%; IC: 0-13.9). Hematological toxicity was grade 1, 2 anemia in 12(59%), and 3 (4%), and grade 1-2 neutropenia (26%). Significant non-hematological toxicity wasgrade 3 fatigue (4%), nausea (4%), and palmoplantar erythrodisesthesia (4%). The mean progressiontime was 3.03 months (IC: 0.96-5.11). The median of survival was 6.13 months (IC: 4.32-7.95). Themean duration of the response in patients responding to treatment was 4.73 months (IC: 4.59-4.88).Conclusion: The pegilated liposomal doxorubicin and cyclophosphamide regime administered topatients with advanced ovary cancer resistant to platinum-based drugs is relatively effective andshows low toxicity</dc:description>
<dc:creator>Grupo ACROSS</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Propósito: Evaluar la eficacia y seguridad en pacientes afectas de cáncer de ovario platinorresistentesde la pauta de adriamicina liposomal pegilada 35 mg/m2 y ciclofosfamida 600mg/m2 día 1 cada28 días, hasta un máximo de 8 ciclos.Material y métodos: Con la metodología de fase II se han reclutado 22 enfermas.Resultados: 5 de 21 enfermas evaluables obtuvieron respuesta (23.8% (IC:5.6-42):4RP (19%IC:2.3-35.8) y 1RC (4.8% IC:0-13.9). La toxicidad hematológica fue de anemia grado 1,2 (59%) 3(4%) y neutropenia grado 1,2 (26%). La toxicidad no hematológica destacable grado 3 fue de fatiga(4%), náusea (4%) y eritrodisestesia palmoplantar (4%). El tiempo medio a la progresión es de 3.03meses (IC:0.96-5.11). La mediana de supervivencia es de 6.13 meses (IC:4.32-7.95). Las pacientescon respuesta tuvieron una mediana de duración de la respuesta de 4.73 meses (IC:4.59-4.88).Conclusión: La pauta de doxorrubicina liposomal pegilada y ciclofosfamida en pacientes concáncer de ovario platinorresistentes es relativamente efectiva y poco tóxica</dc:description>
<dc:source>Oncologia;29(3): 114-123, mar. 2006. tab, graf</dc:source>
<dc:identifier>ibc-044852</dc:identifier>
<dc:title xml:lang="es">Estudio Fase II: doxorrubicina liposomal pegilada y ciclofosfamida en pacientes con cáncer de ovario avanzado platinoresistente</dc:title>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d10229^s22057</dc:subject>
<dc:subject>^d32281</dc:subject>
<dc:subject>^d4420</dc:subject>
<dc:subject>^d4421^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d24023^s22073</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>200603</dc:date>
</metadata>
</record>
</ibecs-document>
